卡达唑胺——一种治疗艰难梭菌相关性腹泻的新药
被引量:4
摘要
艰难梭菌(难辨梭状芽孢杆菌)是一种产芽孢的厌氧性革兰阳性细菌,是引起医院抗生素相关腹泻的最常见细菌,大多寄生在人体肠道内,主要通过产生两种致毒因子(毒素A和毒素B)而发挥毒性。艰难梭菌相关性腹泻(CDAD)是由肠道内的艰难梭菌引起的,通常是过度使用广谱抗生素造成肠道菌群失调的结果,是导致老年住院患者发病和死亡的主要原因。
出处
《中国医院用药评价与分析》
2014年第8期686-689,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
参考文献18
-
1Ananthakrishnan AN.Clostridium difficile infection:epidemiology,risk factors and management[J].Nat Rev Gastro Hepat,2011,1(8):17-26.
-
2Rupnik M,Wilcox MH,Gerding DN.Clostridium difficile infection:new developments in epidemiology and pathogenesis[J].Nat Rev Microbiol,2009,7(7):526-536.
-
3Kamboj M,Khosa P,KaltsasA,et al.Relapse versus reinfection:surveillance of clostridium difficile infection[J].Clin Infect Dis,2011,53(10):1003-1006.
-
4Brazier JS,FawleyW,FreemanJ,et al.Reduced susceptibility of clostridium difficile to metronidazole[J].J Antimicrob Chemother,2001,48(5):741-742.
-
5Baines SD,Connor R,Freeman J,et al.Emergence of reduced susceptibility to metronidazole in Clostridium difficile[J].J Antimicrob Chemother,2008,62(5):1046-1052.
-
6Louie TJ,Miller MA,Mullane KM,et al.OPT-80-003Clinical Study Group.Fidaxomicin versus vancomycin for Clostridium difficile infection[J].N Engl J Med,2011,364(5):422-431.
-
7Cornely OA,Miller MA,Louie TJ,et al.Treatment of first recurrence of Clostridium difficile infection:fidaxomicin versus vancomycin[J].Clin Infect Dis,2012,55(Suppl 2):S154-S161.
-
8Anilrudh A,Venugopal A,Stuart J.Current state of clostridium difficile treatment options[J].Clin Infect Dis,2012,55(1):71-76.
-
9Bauer MP,Kuijper EJ,van Dissel JT.European society of clinical microbiology and infectious diseases(ESCMID):treatment guidance document for clostridium difficile infection(CDI)[J].Clin Microbiol Infect,2009,15(8):1067-1079.
-
10Al-NassirWN,SethiAK,LiY,et al.Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of clostridium difficile-associated disease[J].Antimicrob Agents Chemother,2008,52(7):2403-2406.
同被引文献35
-
1曹艳菊,张豫生,许连壮,米晓森,王惠.微生态制剂对抗生素相关性腹泻预防作用的研究[J].中华医院感染学杂志,2007,17(1):17-19. 被引量:44
-
2张璐,武强.莫西沙星致老年低血糖一例[J].山西医药杂志,2007,36(3):217-217. 被引量:23
-
3Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management [ J ]. Nat Rev Gastroenterol Hepatol, 2011,1(8) :17-26.
-
4Kamboj M, Khosa P, Kaltsas A, et al. Relapse versus reinfection: surveillance of clostridium difficile infection [ J 1. Clin Infect Dis, 2011,53 (10) : 1003-1006.
-
5Venugopal AA, Johnson S. Current state of clostridium difficile treatment options [ J ]. Clin Infect Dis ,2012,55 ( Suppl 1 ) : $71-$76.
-
6Jacqueline K. Kung'u,Olumuyiwa Owolabi,Grace Essien, et al. Promotion of Zinc Tablets with ORS through Child Heahh Weeks Improves Caregiver Knowledge,Attitudes, and Practice on Treatment of Diarrhoea in Nigeria [J]. J Health PopulNutr. 2015 ,33(1) : 9 - 19.
-
7Michelle F Gaffey,Kerri Wazny,Diego G Bassani,et al. Dietary management of childhood diarrhea in low- and middle-income countries: a systematic review [J].BMC Public Health. 2013,13(Suppl 3) : S17.
-
8Thomas Sinmegn Mihrete,Getahun Asres Alemie,Ale- mayehu Shimeka Teferra, et al.Determinants of childhood diarrhea among underfive children in BenishangulGumuz Regional State, North West Ethiopia [J]. BMC Pediatr. 2014,14(14): 102.
-
9周玥,杨明,赵曜,刘福.利奈唑胺不良反应研究进展[J].中国药房,2010,21(2):179-181. 被引量:31
-
10严勤,齐正波,李连茂.抗生素相关性腹泻的临床分析及治疗[J].中国药房,2010,21(6):523-525. 被引量:13
引证文献4
-
1韩凤昭,李振知.抗生素相关性腹泻的危险因素分析及治疗对策[J].中国医院用药评价与分析,2015,15(9):1239-1241. 被引量:26
-
2袁东红,王芳,薛顺和.肠道黏膜保护剂与抗生素联合干预对腹泻预后的改善分析[J].结直肠肛门外科,2016,22(2):192-194.
-
3张瑞.万古霉素治疗艰难梭菌相关性腹泻的疗效及护理干预[J].中国冶金工业医学杂志,2017,34(1):51-51.
-
4祝莉娜.利奈唑胺,莫西沙星及万古霉素治疗艰难梭菌相关性腹泻患者的临床疗效比较[J].中国民康医学,2017,29(7):1-2. 被引量:3
二级引证文献29
-
1夏洪芬,郑华,罗刚.不同途径粪菌移植对艰难梭菌感染患者的疗效及心理状态的影响[J].心理月刊,2021(12):50-51. 被引量:1
-
2任恪聪.从趣味教学谈提高学生素质[J].物理教学,1999,21(12):18-20.
-
3周志敏.肺炎继发抗菌药物相关性腹泻患儿粪便病原体分布及危险因素分析[J].检验医学与临床,2016,13(16):2380-2382. 被引量:8
-
4谢晓云,罗屏,曾志伟.消化内科住院患者抗生素相关性腹泻危险因素分析[J].天津药学,2016,28(5):36-38. 被引量:5
-
5王仪昆,刘璐,苗立成.对1例假膜性肠炎患者的药学监护[J].中国临床药学杂志,2016,25(6):386-388.
-
6郑彩莲,孙建光,杨丽,张素蕊,胡广云.集束化方案降低重症监护病房抗生素相关性腹泻的临床评价[J].中国中西医结合消化杂志,2017,25(1):52-55. 被引量:2
-
7穆英,宋岩,那迪.直肠癌患者肠道微生态与术后腹泻的护理[J].中国微生态学杂志,2017,29(4):431-433. 被引量:7
-
8曾聪.益力多联合三联疗法治疗幽门螺杆菌阳性消化性溃疡的疗效观察[J].现代消化及介入诊疗,2017,22(3):413-414. 被引量:13
-
9刘美英,迟荣香,孙聪玲,邵赏,韩峰.小儿脾虚证与抗菌药物使用关系的研究概况[J].中国医药导报,2017,14(27):52-55.
-
10迟炘,李秀云.蒙脱石散联合布拉氏酵母菌治疗儿童抗生素相关性腹泻的效果及对肠道菌群的影响[J].中国实用医刊,2018,45(12):114-116. 被引量:9
-
1上市新药[J].世界临床药物,2014,35(3).
-
2苏华.治疗艰难梭菌相关性腹泻新药——非达霉素[J].齐鲁药事,2011,30(9):557-558. 被引量:1
-
32012年2月美国FDA公布的药品安全警示[J].药学与临床研究,2012,20(2):108-108.
-
4冯兴为,高嵩玲.新生儿抗生素相关腹泻89例分析[J].临床医学,1998,18(3):35-36.
-
5刘晓川,王静.双歧三联活菌联合整肠生在预防老年患者抗生素相关腹泻中的应用分析[J].中医学报,2014,29(B07):209-209.
-
6宁显忠,邱月.脑出血患者预防性抑酸治疗对艰难梭菌相关性腹泻的影响研究[J].中国药房,2012,23(46):4376-4378. 被引量:1
-
7张翼(编译).美国FDA批准新型大环内酯类抗菌药物非达霉素[J].药品评价,2011,8(18):46-46.
-
8马天驰,秦四梅,杨树金.布拉氏酵母菌治疗抗生素相关腹泻的临床观察[J].海峡药学,2015,27(3):96-97.
-
9姜春梅,刘洋,王京晶,张清,康博欣.抗感染新药非达霉素的药理作用与临床评价[J].中国新药杂志,2011,20(23):2283-2285. 被引量:17
-
10薛冬梅,马明华,余自成.抗生素相关性腹泻治疗新进展[J].世界临床药物,2014,35(7):435-438. 被引量:10